Global expansion Vaxxinova operates production, R&D and sales across 12 countries and is active in more than 75 countries, with ongoing local and headquarter expansion. This presents opportunities to introduce new vaccines and diagnostic services to emerging markets and leverage regional partnerships.

Latin America growth Recent Brazil acquisition of Labovet strengthens Latin American presence, signaling a strategic push in the region. Target opportunities include cross-selling vaccines and diagnostic solutions to expanded distribution channels and leveraging the acquired network.

Poultry focus Active engagement in poultry events and appointment of key poultry account roles indicate a strong market emphasis on poultry health. Sales opportunities include poultry vaccines, diagnostics, and integrated health programs for farm chains and hatcheries.

R&D driven Heavy investment in R&D under EW Group alignment suggests a pipeline of innovative products. Position as a partner who can provide early access, customized diagnostics, and tailored vaccination programs aligned with evolving disease threats.

SME friendly Company profile notes a mid-market revenue range with active hiring and development opportunities. Target small to mid-size veterinary clinics, integrators, and regional distributors with scalable solutions and local support via expanding teams.